ライフサイエンスコーパス: parkinsonian syndrome

1 paminergic lesion associated with an evident parkinsonian syndrome.

2 women presenting with a late-onset isolated parkinsonian syndrome.

3 ented with a 4-year history of a progressive parkinsonian syndrome.

4 iatal dopaminergic neurons, which causes the parkinsonian syndrome.

5 protect against toxins that induce an acute parkinsonian syndrome.

6 nd 70 (42 male, 28 female) as having another parkinsonian syndrome.

7 rotid artery, producing a contralateral hemi-parkinsonian syndrome.

8 CT in participants with clinically uncertain parkinsonian syndrome.

9 longitudinal study of patients with atypical parkinsonian syndromes.

10 ogy or distinguish Parkinson's from atypical parkinsonian syndromes.

11 orticobasal degeneration from other atypical parkinsonian syndromes.

12 istinguish this disorder from other atypical parkinsonian syndromes.

13 work-up of patients with known or suspected parkinsonian syndromes.

14 maging for diagnosing and managing different parkinsonian syndromes.

15 also being applied to the study of atypical parkinsonian syndromes.

16 rvation occur independently in patients with parkinsonian syndromes.

17 impact in patients with clinically uncertain Parkinsonian syndromes.

18 ith respect to the differential diagnosis of Parkinsonian syndromes.

19 ation may occur early in PD but not in other parkinsonian syndromes.

20 ing AIDP in the diagnostic workup for common parkinsonian syndromes.

21 differential diagnosis of neurodegenerative parkinsonian syndromes.

22 maging in patients with clinically uncertain Parkinsonian syndromes.

23 Parkinsonian syndromes, also common causes of dementia,

24 f 106 participants with clinically uncertain parkinsonian syndrome and diagnostic 3-T SW MRI examinat

25 f specific patterns associated with atypical parkinsonian syndromes and classic Parkinson's disease w

26 riatal dopaminergic pathways as seen in most parkinsonian syndromes and in some cases of illicit drug

27 actical use in the differential diagnosis of Parkinsonian syndromes and indeterminate tremors.

28 nge of neurodegenerative diseases, including parkinsonian syndromes and motor neuron disease.

29 mination (ACE-R) could differentiate between parkinsonian syndromes and reflect longitudinal changes

30 metabolic diseases, and genetic dystonic or parkinsonian syndromes) and are, therefore, frequently m

31 in networks in Parkinson's disease, atypical parkinsonian syndromes, and other movement disorders.

32 These findings indicate that (1) in parkinsonian syndromes apart from PSP, the saccade-gener

33 patients with clinically suspected atypical parkinsonian syndrome (APS) were prospectively recruited

34 degree of clinical overlap between atypical parkinsonian syndromes (APS) and Parkinson's disease (PD

35 city for Parkinson Disease (PD) vs. atypical parkinsonian syndromes (APS), in line with the results o

36 esirable in patients with suspected atypical parkinsonian syndromes (APSs) for optimal treatment and

37 This is important as atypical parkinsonian syndromes (APSs) such as progressive supran

38 atistical analyses for diagnosis of atypical parkinsonian syndromes are 91.4% and 90.6%, respectively

39 Atypical parkinsonian syndromes are distinguished from Parkinson'

40 luded participants with clinically uncertain parkinsonian syndrome between May 2016 and May 2019.

41 egenerative conditions, such as dementia and parkinsonian syndromes, both for research and for clinic

42 It has been previously reported that a Parkinsonian syndrome can be elicited in the common gold

43 trahydropyridine (MPTP) to cats results in a parkinsonian syndrome characterized by rigidity, akinesi

44 but are rare; most cases with a fairly pure parkinsonian syndrome (eg, young-onset Parkinson's disea

45 On examination, he showed a severe parkinsonian syndrome featuring bradykinesia, rigidity (

46 ese techniques poorly differentiate atypical parkinsonian syndromes from PD, and their availability i

47 rogression were compared with other atypical Parkinsonian syndromes from previous QSBB studies.

48 improvements in the characterisation of the parkinsonian syndromes have led to improvements in clini

49 movements in 23 patients with the following parkinsonian syndromes: idiopathic parkinsonism (PD), mu

50 gnosis of Parkinson disease (PD) or atypical parkinsonian syndrome in clinical uncertainty.

51 -tetrahydropyridine (MPTP), which produces a Parkinsonian syndrome in experimental animals and humans

52 1) were significantly lower in patients with parkinsonian syndromes in drug-off condition than in hea

53 with spectra obtained from 20 patients with parkinsonian syndromes in drug-on and drug-off condition

54 o compare healthy subjects and patients with parkinsonian syndromes in drug-on or drug-off conditions

55 contributor to the differential diagnosis of parkinsonian syndromes in the correct clinical context.

56 to improve diagnostic accuracy for atypical parkinsonian syndromes in vivo.

57 supranuclear palsy (PSP) overlap with other parkinsonian syndromes, including multiple system atroph

58 between Parkinson disease (PD) and atypical parkinsonian syndromes, including multiple-system atroph

59 ased automated algorithm in the diagnosis of parkinsonian syndromes, including unpublished data from

60 idiopathic Parkinson's disease from atypical parkinsonian syndromes is challenging, especially in the

61 at 98.6% (72 out of 73), while for the other parkinsonian syndromes it was 71.4% (50 out of 70).

62 supranuclear palsy is considered an atypical parkinsonian syndrome, it is not known whether patients

63 lysosomal ATPase ATP13A2, a gene linked to a parkinsonian syndrome (Kufor-Rakeb syndrome), in brain s

64 rty-seven patients with clinically uncertain Parkinsonian syndromes (mean age +/- SD, 56.9 +/- 14.9 y

65 anuclear palsy (the two most common atypical parkinsonian syndromes) on a single case basis.

66 ficient to distinguish between IPD and other parkinsonian syndromes, particularly in the early stages

67 high diagnostic accuracy for differentiating parkinsonian syndromes (PS), from essential tremor and p

68 ols, but its utility in clinically uncertain parkinsonian syndromes remains unclear.

69 Patients presenting with parkinsonian syndromes share many clinical features, whi

70 Patients with FoG, which is a feature of parkinsonian syndromes, show variability in gait metrics

71 In some patients with suspected parkinsonian syndromes, SPECT imaging with ((123)I)ioflu

72 on In participants with clinically uncertain parkinsonian syndrome, STS absence on 3-T brain SW MRI s

73 that is difficult to distinguish from other parkinsonian syndromes such as multiple-system atrophy (

74 ly better at discriminating between atypical parkinsonian syndromes than were the cognitive domains;

75 In comparison with other Parkinsonian syndromes the patients were older and had a

76 Fourteen patients with parkinsonian syndromes underwent (18)F-desmethoxyfallypr

77 When compared with other Parkinsonian syndromes, VP had an older age of onset.

78 rs to diseases that manifest with a dominant parkinsonian syndrome, which can be typical or atypical,